Jubilant Life Sciences’ Arm Gets ANDA Final Approval For OCD Capsules

Jubilant Life Sciences Limited, an integrated global Pharmaceutical and Life Sciences Company, announced on Tuesday that Jubilant Pharma Limited, a material wholly owned subsidiary of the Company, through one of its wholly owned subsidiaries, has received Abbreviated New Drug Application (ANDA) final approval for Clomipramine Hydrochloride Capsules USP 25mg, 50mg and 75mg, the generic version of Anafranil® of SpecGx LLC, which is used for the treatment of obsessions and compulsions in patients with Obsessive-Compulsive Disorder (OCD).

As on June 30, 2019, Jubilant had a total of 96 ANDAs for Oral Solids filed in the US, of which 61 had been approved and 15 Injectable filings, of which 13 had been approved.

Jubilant Life Sciences Limited is an integrated global pharmaceutical and life sciences company engaged in Pharmaceuticals, Life Science Ingredients and Drug Discovery Solutions.

Stock View:

Jubilant Life Sciences Ltd ended at Rs541.30 up by Rs35.95 or 7.11% from its previous closing of Rs505.35 on the BSE.

The scrip opened at Rs504 and touched a high and low of Rs549 and Rs504 respectively. A total of 5,25,732 (NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs8,622.91cr. – IIFL

Share this:

Related Post

Stay Updated on Medical Equipment and Devices industry.
Receive our Daily Newsletter.